Key result
Pfizer-BioNTech COVID-19 vaccine may trigger anti-HMG-CoA reductase immune-mediated necrotizing myopathy.
Why the study?
The possible adverse effects of COVID-19 vaccines, including immune-mediated necrotizing myopathy, remain to be identified and reported.
Can the Pfizer-BioNTech COVID-19 vaccine trigger anti-HMG-CoA reductase necrotizing myopathy?
Case Report (n=1)
Can the Pfizer-BioNTech COVID-19 vaccine trigger anti-HMG-CoA reductase necrotizing myopathy?
This is the first case report suggesting that a COVID-19 vaccine may trigger anti-HMG-CoA reductase necrotizing myopathy.
Case of post-vaccination anti-HMGCR IMNM is hypothesis-generating; leaves open any causal association requiring larger surveillance studies.
The new coronavirus (COVID-19) pandemic has resulted in the unprecedented production of vaccines. In this context, the possible adverse effects remain to be identified and reported. In this article, we report the case of a young female patient who developed anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMG-CoA) immune-mediated necrotizing myositis (IMNM) after receiving the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine. The diagnosis of probable post-vaccination IMNM was made due to the absence of other factors that may have led to the development of autoantibodies (medicines; e.g., statins, drugs) and the temporal relationship between exposure and event. This case report is the first to suggest that a COVID-19 vaccine may trigger anti-HMG-CoA reductase necrotizing myopathy.
No takes yet. Share an insight, caveat, or question.
Carvalho et al. (2023) conducted a case report in Anti-HMG-CoA immune-mediated necrotizing myositis (IMNM) (n=1). Pfizer-BioNTech (BNT162b2) COVID-19 vaccine was evaluated on Development of anti-HMG-CoA reductase necrotizing myopathy. The Pfizer-BioNTech (BNT162b2) COVID-19 vaccine may trigger anti-HMG-CoA reductase immune-mediated necrotizing myopathy, as observed in a young female patient.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: